This paper is in the following e-collection/theme issue:

Prevention and Health Promotion (576) Secondary Use of Clinical Data for Research and Surveillance (266) Infectious Diseases (non-STD/STI) (1288) Influenza and Influenza-Like-Illness (ILI) Surveillance (90) Innovative Methods in Public Health and Surveillance (264) Surveillance Systems (389)

Published on in Vol 5 , No 4 (2019) :Oct-Dec

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/12016, first published .
Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study

Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study

Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study

Authors of this article:

Simon de Lusignan 1 Author Orcid Image ;   Ana Correa 1 Author Orcid Image ;   Gaël Dos Santos 2 Author Orcid Image ;   Nadia Meyer 2 Author Orcid Image ;   François Haguinet 2 Author Orcid Image ;   Rebecca Webb 1 Author Orcid Image ;   Christopher McGee 1, 3 Author Orcid Image ;   Rachel Byford 1 Author Orcid Image ;   Ivelina Yonova 1, 3 Author Orcid Image ;   Sameera Pathirannehelage 1 Author Orcid Image ;   Filipa Matos Ferreira 1 Author Orcid Image ;   Simon Jones 1, 4 Author Orcid Image
Article Authors Cited by (7) Tweetations (4) Metrics

Journals

  1. Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Human Vaccines & Immunotherapeutics 2019;15(11):2624 View
  2. Dos Santos G, Nguyen B, Damaso S, Godderis L, Martínez-Gómez X, Eckermann T, Loos H, Salamanca de la Cueva I, Shende V, Schmidt A, Yeakey A. Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season. Drug Safety 2020;43(3):265 View
  3. Dos Santos G, Shende V, Damaso S, Yeakey A. Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis. Advances in Therapy 2019;36(12):3340 View
  4. Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, Eckermann T, Godderis L, Martínez Gómez X, Godard E, Soler M, Yousefi M, Salamanca de la Cueva I, Nwoji U. Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season. Infectious Diseases and Therapy 2022;11(1):463 View
  5. Moeller-Arendt M, van de Witte S, Nauta J, de Voogd H, Rogoll J, Nisslein T. Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons. Vaccine 2023;41(2):606 View
  6. Salamanca de la Cueva I, Cinconze E, Eckermann T, Nwoji U, Godderis L, Lu E, Martínez-Gómez X, Wang H, Yanni E. Safety Profile of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season. Drug Safety 2021;44(12):1375 View
  7. Dos Santos G, Eckermann T, Martínez‐Gómez X, Parra J, Nwoji U, Salamanca de la Cueva I. Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient‐reported outcome system for vaccine safety remote monitoring. Influenza and Other Respiratory Viruses 2023;17(3) View